Sleep, Circadian Hormonal Dysregulation, and Breast Cancer Survival

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT00519168
First received: August 20, 2007
Last updated: May 31, 2013
Last verified: May 2013
  Purpose

Recent research provides evidence that disrupted circadian rhythms, including hormonal patterns and sleep, are associated with increased risk of breast cancer incidence and faster progression to mortality. We have observed that a loss of normal diurnal cortisol rhythm associated with more awakenings during the night predicts early mortality with metastatic breast cancer. Other recent studies have shown that nighttime shift work is associated with higher breast cancer incidence, and in a murine model disrupting circadian cortisol cycles produced a doubling of implanted tumor growth. There is also recent evidence that abnormal clock genes are associated with cancer. However, it is not clear whether sleep disruption per se affects breast cancer progression, or whether such an effect is mediated by hormonal and immune dysregulation of this prevalent and hormone-mediated cancer. We propose to study sleep disruption as a prognostic factor in the progression of metastatic breast cancer. We will also examine sleep patterns in association with disrupted circadian rhythms of cortisol, ACTH, and melatonin as well as measures of immune function known to be salient to breast cancer progression. These are natural killer cell cytoxicity and specific cytokine, IL-6. We plan to recruit 105 women 45 years through 75 years with metastatic or recurrent breast cancer and 20 age and SES-matched controls for a two-week at home sleep study with Actiwatch and two nights of in-home EEG monitoring, followed by 28 hours of continuous blood sampling and one night of EEG sleep monitoring in our lab at Stanford. This will provide a full examination of circadian hormones associated with sleep patterns. We will relate these assessments to the subsequent course of breast cancer progression. Results of this study will provide specific evidence regarding how improved sleep management may affect the course of breast cancer. Aim 1: To study 24-hr diurnal rhythms of HPA axis hormones and melatonin in women with metastatic or recurrent breast cancer. Hypothesis 1: Women with metastatic or recurrent breast cancer will have reduced amplitude and disrupted phase of 24-hr diurnal rhythms of cortisol, ACTH, and melatonin. Aim 2: To describe sleep disruption in women with metastatic breast cancer and examine psychosocial, endocrine, and immune factors that may be associated with sleep disruption. Hypothesis 2: Women with metastatic or recurrent breast cancer will have a higher incidence of both at home and laboratory-examined sleep disruption than control women without breast cancer. Hypothesis 3: Poorer sleep quality will be associated with more pain, more emotional suppression in response to stressors, less emotional support, greater depression and anxiety, and greater perceived and traumatic stress. Hypothesis 4: Poorer sleep quality and quantity of sleep and daytime sleepiness and fatigue will be associated with abnormal circadian neuroendocrine (i.e., cortisol, ACTH, and melatonin) and immune patterns (i.e., suppressed day and night time NK activity and loss of NK rhythms; increased day time IL-6 levels and /or loss of IL-6 rhythm). Aim 3: To study the relationship between sleep disruption and survival time among metastatic and recurrent breast cancer patients. Hypothesis 5: Poorer sleep quality and quantity of sleep will predict shorter survival. Hypothesis 6: Reduced diurnal amplitude and an abnormal phase of cortisol will predict shorter survival. Explanatory Aim 4: To investigate whether sleep disruption mediates the relation of psychosocial factors to health outcomes.


Condition Intervention
Breast Cancer
Procedure: Urine sample
Device: Electrode sleep recorder
Procedure: phlebotomy

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Sleep, Circadian, Hormonal Dysregulation, and Breast Cancer Survival

Resource links provided by NLM:


Further study details as provided by Stanford University:

Biospecimen Retention:   Samples Without DNA

Saliva and blood


Estimated Enrollment: 125
Study Start Date: September 2006
Estimated Study Completion Date: August 2017
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Urine sample
    Standard of care
    Other Name: urine test
    Device: Electrode sleep recorder
    Standard of care
    Other Name: Digital sleep recorder
    Procedure: phlebotomy
    Standard of care
    Other Name: blood draw
  Eligibility

Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

women with breast cancer

Criteria

Inclusion Criteria:

Inclusion criteria for women with breast cancer:

  1. Female
  2. Between 45 and 75 years old (45<=>75)
  3. Documented metastatic or recurrent breast cancer
  4. Karnofsky rating of at least 70% (measure of physical ability used to assess medically ill patients)
  5. Residence within the Greater San Francisco Bay Area
  6. Proficiency in English sufficient to complete questionnaires
  7. Postmenopausal
  8. Non smoker (occasional smoking will be ok, they need to agree to stop smoking during study participation. If smoking cessation will cause withdrawal, they can not participate)
  9. Willing to go through a 30 day washout period if they are currently on Decadron or any other corticosteroids (depending on the dose, may be able to reduce 30 days to 2 weeks)
  10. If taking Benzodiazepines, willing to stop 3 days before the collection of physiological measures, such as the 2 week at home sleep recordings and then the 3 days before and during the GCRC (if not possible, washout period may be reduced to 3 days before and during the CTRU/GCRC stay)
  11. Willingness to discontinue taking melatonin one week before the CTRU/GCRC stay
  12. Willingness to discontinue any current sleeping medications 3 days before 2 week at home sleep data collection through the end of study participation (if not possible, washout period may be reduced to 3 days before and during the CTRU/GCRC stay)
  13. Willingness to abstain from traveling 2 or more time zones away from California (Pacific time), two weeks before and during participation in the study
  14. Willing/able to refrain from doing shift-work in a non-traditional schedule (such as 4pm to midnight or 10pm to 6am) starting two weeks before at home sleep collection through the end of study participation.
  15. Agree to catheterization for blood sample collection
  16. Agrees with the use of heparin during the blood draws (used to keep IV line from clotting)
  17. Has graduated high school or obtained GED
  18. US Citizen or resident viable for payment, legally

Inclusion criteria for healthy controls:

  1. Female
  2. Between 45 and 75 years old (45<=>75)
  3. No history of any type of cancer
  4. Residence within the Greater San Francisco Bay Area
  5. Proficiency in English to complete questionnaires
  6. Post Menopausal
  7. Non-smoker (occasional smoking will be ok, they need to agree to stop smoking during study participation. If smoking cessation will cause withdrawal, they can not participate)
  8. If taking benzodiazepines, willing to stop 3 days before the collection of physiological measures, such as the 2 week at home sleep recordings and then the 3 days before and during the GCRC (if not possible, washout period may be reduced to 3 days before and during the CTRU/GCRC stay)
  9. Willingness to discontinue taking melatonin one week before the CTRU/GCRC stay
  10. Willingness to discontinue any current sleeping medications 3 days before 2 week at home sleep data collection through the end of study participation (if not possible, washout period may be reduced to 3 days before and during the CTRU/GCRC stay)
  11. Willingness to abstain from traveling 2 or more time zones away from California (Pacific time), two weeks before and during participation in the study
  12. Willing/able to refrain from doing shift-work in a non-traditional schedule (such as 4pm to midnight or 10pm to 6am) starting two weeks before at home sleep collection through the end of study participation
  13. Agree to catheterization for blood sample collection
  14. Agrees with the use of heparin during the blood draws (used to keep IV line from clotting)
  15. Has graduated high school or obtained GED
  16. US Citizen or resident viable for payment, legally
  17. Pittsburgh Sleep Quality Index (PSQI) score >6

Exclusion Criteria:Exclusion criteria for women with breast cancer:

  1. Other active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix
  2. Concurrent medical condition likely to influence short term survival (such as liver disease, asthma etc, depending on severity)
  3. History of major psychiatric illness that required hospitalization or medication
  4. Substance Dependence or abuse
  5. Low hematocrit (up to the digression of the PI, may be able to participate in parts of the protocol)
  6. Bilateral lymph nodes removed
  7. Diagnosis of diabetes (need to check with PI, some mild cases of diabetes may be ok)
  8. Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis
  9. PICC line too close to the few available veins, viable for catheterization (too high of a risk for infection/complication), and is on the only arm which did not have lymph node surgery

Exclusion criteria for healthy controls:

  1. Concurrent medical condition likely to influence short term survival (such as liver disease, asthma etc, depending on severity)
  2. History of major psychiatric illness that required hospitalization or medication
  3. Substance dependence or abuse
  4. Low hematocrit (up to the digression of the PI, may be able to participate in parts of the protocol)
  5. Diagnosis of diabetes (need to check with PI, some mild cases of diabetes may be ok)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00519168

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: David Spiegel Stanford University
  More Information

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00519168     History of Changes
Other Study ID Numbers: BRSADJ0013, 97312, BRSADJ0013
Study First Received: August 20, 2007
Last Updated: May 31, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on August 18, 2014